ArticleOncology and therapy2026

A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain".

Virginia Lozano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.